p53 mutation spectrum in relation to GSTM1, CYP1A1 and CYP2E1 in surgically treated patients with non-small cell lung cancer

Pharmacogenetics

Volumn 8, Issue 6, 1998, Pages 503-511

  Przygodzki, Ronald M ^a,b   Bennett, William P ^a   Guinee Jr , Donald G ^a,b   Khan, Mohammed A ^a   Freedman, Andrew ^a   Shields, Peter G ^a   Travis, William D ^b   Jett, James R ^c   Tazelaar, Henry ^c   Pairolero, Peter ^c   Trastek, Victor ^c   Liotta, Lance A ^a   Harris, Curtis C ^a   Caporaso, Neil E ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

^c MAYO CLINIC   (United States)

Author keywords

CYP1A1; CYP2E1; GSTM1; Lung cancer; p53

Indexed keywords

CYTOCHROME P450; GLUTATHIONE TRANSFERASE; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CONTROLLED STUDY; DEMOGRAPHY; DNA POLYMORPHISM; DNA SEQUENCE; EXON; FAMILY HISTORY; FEMALE; GENE ACTIVATION; GENE MUTATION; GENETIC MARKER; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OCCUPATION; PRIORITY JOURNAL; SMOKING; SURVIVAL;

EID: 0032423862     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199812000-00007     Document Type: Article

References (49)

1. Alexandrov K, Rojas M, Geneste O, et al. An improved fluoremetric assay for dosimetry of benzo(a)pyrene diol-epoxide-DNA adducts in smoker's lungs and AHH activity. Cancer Res 1992; 52:6248-6253.
2. Ambrosone CB, Freudenheim JL, Graham S, Marshall JR, Vena JE, Brasure JR, et al. Cytochrome P4501A1 and glutathione S-transferase (m1) genetic polymorphisms and postmenopausal breast cancer risk. Cancer Res 1995; 55:3483-3485.
3. Anttila S, Hirvonen A, Husgafvel PK, Karjalainen A, Nurminen T, Vainio H. Combined effect of CYP1A1 inducibility and GTSM1 polymorphisms on histological type of lung cancer. Carcinogenesis 1994; 15:1133-1135.
4. Bartsch H, Montesano R. Relevance of nitrosamines to human cancer. Carcinogenesis 1984; 5:1381-1393.
5. Bartsch H, Petruzzelli S, De Flora S, Hietanen E, Camus AM, Castegnaro M, et al. Carcinogen metabolism and DNA adducts in human lung tissues as affected by tobacco smoking or metabolic phenotype: a case-control study on lung cancer patients. Mutat Res 1991; 250:103-114.
6. Brash DE, Rudolph JA, Simon JA, Lin A, McKenna GJ, Baden HP, et al. A role for sunlight in skin cancer. UV-induced p53 mutations in squamous cell carcinoma. Proc. Natl Acad Sci USA 1991; 88:10124-10128.
7. Caporaso N, Goldstein A. Cancer genes: single and susceptibility: exposing the difference. Pharmacogenetics 1995; 5:59-63.
8. Caporaso N, Landi MT, Vineis P. Relevance of metabolic polymorphisms to human carcinogenesis: evaluation of epidemiologic evidence. Pharmacogenetics 1991; 1:4-19.
9. Cascorbi I, Brockmoller J, Roots I. A C4887A polymorphism in exon 7 of human CYP1A1: population frequency, mutation linkages and impact on lung cancer susceptibility. Cancer Res 1996; 56:4965-4969.
10. Colby TV, Koss MN, Travis WD. Tumors of the lower respiratory tract. 3rd ed. Vol. 13. Washington DC: Armed Forced Institute of Pathology: 1995.
11. Eposito V, Baldi A, DeLuca A, Michelli P, Mazzarella G, Baldi F, et al. Prognostic value of p53 in non-small cell lung cancer; relationship with proliferating cell antigen and cigarette smoking. Hum Pathol 1997; 28:233-237.
12. Geneste O, Camus A-M, Castegnaro M, Petruzzelli S, Macchiarini P, Giuntini C, et al. Comparison of pulmonary DNA-adduct levels, measured by 32P-postlabelling and aryl hydrocarbon hydroxylase activity in the lung and parenchyma of smokers and non-smokers. Carcinogenesis 1991; 12:1301-1305.
13. Goto I, Yoneda S, Yamamoto M, Kawajiri K. Prognostic significance of germ line polymorphism of the CYP1A1 and glutathione S-transferase genes in patients with non-small cell lung cancer. Cancer Res 1996; 56:3725-3730.
14. Greenblatt MS, Bennett WP, Holstein M, Harris CC. Mutations in the p53 tumour suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994; 54:4855-4878.
15. Greenblatt MS, Grollman AP, Harris CC. Deletions and insertions in the p53 tumor suppressor gene in human cancers: confirmation of the DNA polymerase slippage/misalignment model. Cancer Res 1996; 56:2130-2136.
16. Guinee DG, Travis WD, Trivers GE, De BV, Cawley H, Welsh JA, et al. Gender comparisons in human lung cancer, analysis of p53 mutations, anti-p53 serum antibodies and C-erbB-2 expression. Carcinogenesis 1995; 16:993-1002.
17. Harris CC. Interindividual variation among humans in carcinogen metabolism. DNA adduct formation and DNA repair. Carcinogenesis 1989; 10:1563-1566.
18. Hayashi S, Watanabe J, Nakachi K, Kawajiri K. Genetic linkage of lung cancer-associated Msp1 polymorphisms with amino acid replacement in the heme binding region of the human cytochrome p4501a1 gene. J Biochem (Tokyo) 1991; 110:407-411.
19. Hirvonen A, Husgafvel PK, Karjalainen A, Anttila S, Vainio H. Point-mutational Msp1 and Ile-Val polymorphisms closely linked in the CYP1A1 gene; lack of association with susceptibility to lung cancer in a Finnish study population. Cancer Epidemiol Biomarkers Prev 1992; 1:485-489.
20. Hirvonen A, Husgafvel PK, Anttila S, Vainio H. The GSTM1 null genotype as a potential risk modifier for squamous cell carcinoma of the lung. Carcinogenesis 1993a; 14:1479-1481.
21. Hirvonen A, Husgafvel PK, Anttila S, Karjalainen A, Vainio H. The human CYP2E1 gene and lung cancer. Dral and Rsal restriction fragment length polymorphisms in a Finnish study population. Carcinogenesis 1993b; 14:85-88.
22. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutational status in human cancers. Science 1991; 253:49-53.
23. Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ, Harris CC. Mutational hotspot to the p53 gene in human hepatocellular carcinomas. Nature 1991; 350:427-428.
24. Ichiba M, Hagmar L, Rannug A, Hogstedt B, Alexandrie A-K, Carstensen U, Hemminki K. Aromatic DNA adducts, micronuclei, and genetic polymorphism for CYP1A1 and GST1 in chimney sweeps. Carcinogenesis 1994; 14:1347-1352.
25. Kato S, Shields PG, Caporaso NE, Sugimura H, Trivers GE, Tucker MA, et al. Analysis of cytochrome P450 2E1 genetic polymorphisms in relation to human lung cancer. Cancer Epidemiol Biomarkers Prev 1994; 3:515-518.
26. Kato S, Bowman ED, Harrington AM, Blomeke B, Shields PG. Human lung carcinogen-DNA adduct levels mediated by genetic polymorphisms in vivo [see comments]. J Natl Cancer Inst 1995; 87:902-907.
27. Kato S, Shields PG, Caporaso NE, Hoover RN, Trump BF, Sugimura H, et al. Cytochrome P450IIE1 genetic polymorphisms, racial variation and lung cancer risk. Cancer Res 1992; 52:6712-6715.
28. Kawajiri K, Fujii-Kuriyama Y. P450 and human cancer. Jpn J Cancer Res 1991; 82:1325-1335.
29. Kawajiri K, Nakchi K, Imai K, Yoshii A, Shinoda N, Watanabe J. Identification of genetically high risk individuals to lung cancer by DNA polymorphisms of the cytochrome P4501A1 gene. FEBS 1990; 263:131-133.
30. Kawajiri K, Nakchi K, Imai K, Watanabe J, Hayashi S. The CYP1A1 gene and cancer susceptibility. Crit Rev Oncol Hematol 1993; 14:77-87.
31. Kawajiri K, Hidetaka E, Nakachi K, Sekiya T, Yamamoto M. Association of CYP1A1 germ line polymorphisms with mutations of the p53 gene in lung cancer. Cancer Res 1996; 56:72-76.
32. London SJ, Daly AK, Cooper J, Navidi WC, Carpenter CL, Idle JR. Polymorphism of glutathione-S-transferase M1 and lung cancer risk among African-Americans and Caucasians in Los Angeles County, California. J Natl Cancer 1995; 87:1246-1253.
33. Mannervik B, Danielson UH. Glutathione transferases - structure and catalytic activity. CRC Critical Rev Biochem 1988; 23:283-337.
34. McWilliams JE, Sanderson BJ, Harris EL, Richert-Boe KE, Henner WD. Glutathione S-transferase M1 (GSTM1) deficiency and lung cancer risk. Cancer Epidemiol Biomarkers Prev 1995; 4:589-594.
35. Nakachi K, Imai K, Hayashi S, Watanabe J, Kawajiri K. Genetic susceptibility to squamous cell carcinoma of the lung in relation to cigarette smoking dose. Cancer Res 1991; 51:5177-5180.
36. Nakachi K, Imai K, Hayashi S, Kawajiri K. Polymorphisms of the CYP1A1 and glutathione S-transferase genes associated with susceptibility to lung cancer in relation to cigarette dose in a Japanese population. Cancer Res 1993; 53:2994-2999.
37. Persson I, Johansson I, Bergling H, Dahl ML, Seidegard J, Rylander R, et al. Genetic polymorphism of cytochrome P4502E1 in a Swedish population. Relationship to incidence of lung cancer. FEBS Lett 1993; 319:207-211.
38. Ryberg D, Kure E, Lystad S, Skaug V, Stangeland L, Mercy I, et al. p53 mutations in lung tumors: relationship to putative susceptibility markers for cancer. Cancer Res 1994; 54:1551-1555.
39. SAS Institute. SAS User's Guide 5th ed. Cary, NC; 1985.
40. Seidegard J, Pero RW, Miller DG, Beattie EJ. A glulathione transferase in human leukocytees as a marker for the susceptibility to lung cancer. Carcinogenesis 1986; 7:751-753.
41. Seidegard J, Vorachek WR, Pero RW, Pearson WR. Hereditary differences in the expression of the human glutathione transferase activity of trans-stilbene oxide are due to a gene deletion. Proc Nat Acad Sci USA 1988; 85:7293-7297.
42. Seidegard J, Pero RW, Markowitz MM, Roush G, Miller DG, Beattie EJ. Isoenzyme(s) of glutathione transferase (class Mu) as a marker for the susceptibility to lung cancer: a follow up study. Carcinogenesis 1990; 11:33-36.
43. Shields PG, Harris CC. Molecular epidemiology and the genetics of environmental cancer. JAMA 1991; 266:681-687.
44. Shields PG, Bowman ED, Harrington AM, Doan VT, West on A. Polycyclic aromatic hydrocarbon-DNA adducts in human lung and cancer susceptibility genes. Cancer Res 1993a; 53:3486-3492.
45. Shields PG, Caporaso NE, Falk RT, Sugimura H, Trivers GE, Trump BF, et al. Lung cancer, race, and a CYP1A1 genetic polymorphism. Cancer Epidemiol Biomarkers Prev 1993b; 2:481-485.
46. Tefre T, Ryberg D, Hangen A, Nebert DW, Skaug V, Brgger A, et al. Human CYP1A1 (cytochrome P(1)450) gene: lack of association between the Msp I restriction fragment length polymorphism and incidence of lung cancer in a Norwegian population. Pharmacogenetics 1991; 1:20-25.
47. Uematsu F, Kikuchi H, Motomiya M, Abe T, Sagami I, Ohmachi T, et al. Association between restriction fragment length polymorphism of the human cytochrome p450IIE1 gene and susceptibility to lung cancer. Jpn J Cancer Res 1991; 82:254-256.
48. van Poppel G, de Vogel N, van Balderen PJ, Kok FJ. Increased cytogenetic damage in smokers deficient in glutathione S-transferase isozyme Mu. Carcinogenesis 1992; 13:303-305.
49. Wu X, Shi H, Jiang H, Kemp B, Ki Hong W, Delclos GL, et al. Associations between cytochrome P4502E1 genotype, mutagen sensitivity, cigarette smoking and susceptibility to lung cancer. Carcinogenesis 1997; 18:967-973.